Searching…
May 24, 2010 · Docetaxel is approved throughout the world for the treatment of breast cancer and has demonstrated preclinical synergy with bevacizumab. 14 The randomized, double-blind, phase III study Avastin And Doce...
Feb 19, 2013 · The AVADO trial was a double-blind, placebo-controlled, randomised phase 3 trial evaluating bevacizumab in combination with docetaxel as first-line therapy for HER2-negative LR/mBC.
Nov 1, 2013 · AVADO and RIBBON-1 were double-blinded placebo-controlled trials, whereas E2100 was an open-label study. The chemotherapy backbone was weekly paclitaxel in E2100, 3-weekly docetaxel in AVADO, capecitabin...
Jun 27, 2017 · The AVADO trial was a 3-arm trial, in which HER2-negative locally recurrent or metastatic breast cancer patients were randomized on a 1:1:1 basis to receive bevacizumab 7.5 mg/kg plus docetaxel 100 mg/m...
Sep 10, 2010 · AVADO 研究的最新结果报告了多西他赛和贝伐珠单抗组合的类似结果。 AVADO 研究进一步证实了贝伐珠单抗的剂量为 15 mg/kg BW。 由于在转移性乳腺癌 (MBC) 中经常使用联合化疗，因此应研究使用贝伐珠单抗和至少 2 种细胞毒性药物的方案。
结论 该试验再次验证了ECOG 2100和AVADO试验的结果。 在转移性乳腺癌一线治疗中，贝伐单抗联合卡培他滨、紫杉或蒽环类方案化疗可显著改善患者的PFS和ORR，同时其安全性与既往的Ⅲ期临床研究结果一致。
Presentation discussed in this issue: Miles DW et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, Phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared wi...
Sep 3, 2021 · 随后在2010年7月20日FDA药物评估和研究中心的肿瘤药物咨询委员会（ODAC）上，FDA综合E2100，AVADO和RIBBON-1这3项临床试验的疗效和安全数据，发现贝伐珠单抗仅能延长患者PFS，却不能…
Abstract Five randomized phase III trials - AVF2119g, E2100, AVADO, RIBBON-1, and RIBBON-2 - have reported data on the efficacy and safety of bevacizumab, combined with a variety of chemotherapy agents and in various ...
将贝伐单抗与一线化疗相结合可显着提高 HER2 阴性转移性乳腺癌 (mBC) 的无进展生存期 (PFS)。然而，确定从贝伐单抗中获益最多的患者仍然难以确定。AVADO 试验包括广泛的可选探索性生物标志物计划。
